CAI
Company Description
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 812.03M | 412.26M | 306.13M | 258.49M | 294.01M | 416.54M | 432.10M | 348.39M | 294.35M | 249.67M | 227.59M | 212.41M |
| Net Income | (537.96M) | (281.89M) | (341.42M) | (320.83M) | 27.73M | 31.01M | 78.60M | 72.06M | 6.00M | 26.84M | 60.27M | 63.93M |
| EPS | -1.90 | -2.70 | -1.82 | -1.57 | 1.55 | 1.72 | 3.97 | 3.74 | 0.31 | 1.29 | 2.91 | 2.89 |
| Free Cash Flow | 66.89M | (253.64M) | (298.42M) | (327.96M) | 57.57M | (65.14M) | (633.07M) | (346.98M) | (121.99M) | (242.04M) | (167.62M) | (188.02M) |
| FCF / Share | 0.04 | -1.00 | -1.17 | -1.29 | 3.21 | -3.62 | -31.94 | -18.02 | -6.31 | -11.65 | -8.09 | -8.49 |
| Operating CF | 83.16M | (245.20M) | (276.10M) | (285.71M) | 277.02M | 254.00M | 179.77M | 155.19M | 129.26M | 147.37M | 139.69M | 124.19M |
| Total Assets | 1.13B | 343.73M | 412.90M | 717.42M | 2.61B | 2.90B | 3.01B | 2.43B | 2.06B | 1.99B | 1.80B | 1.68B |
| Total Debt | 378.99M | 424.26M | 217.27M | 270.87M | 1.75B | 2.10B | 2.16B | 1.70B | 1.48B | 1.43B | 1.26B | 1.13B |
| Cash & Equiv | 797.80M | 63.95M | 56.40M | 107.19M | 53.55M | 46.46M | 45.31M | 35.42M | 46.13M | 52.55M | 53.82M | 45.74M |
| Book Value | 577.31M | (2.50B) | (2.14B) | (1.70B) | 702.24M | 693.24M | 701.13M | 563.85M | 457.50M | 460.34M | 442.12M | 414.53M |
| Return on Equity | -0.93 | N/A | N/A | N/A | 0.04 | 0.04 | 0.11 | 0.13 | 0.01 | 0.06 | 0.14 | 0.15 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q2 2024 | Q1 2024 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 216.17M | 292.89M | 216.83M | 181.40M | 120.92M | 100.05M | 80.68M | 100.83M | 85.69M | 80.80M | 64.32M | 79.05M |
| Net Income | (510,000) | 81.96M | 24.32M | (71.79M) | (102.58M) | (66.19M) | (111.03M) | 51.16M | 37.94M | 35.74M | 14.25M | 15.44M |
| EPS | -0.00 | 0.29 | 0.09 | -1.93 | -0.40 | -0.35 | -0.53 | 2.95 | 2.20 | 2.07 | 0.80 | 0.88 |
| Free Cash Flow | 22.53M | 39.69M | 55.33M | 5.90M | (34.03M) | (65.51M) | (75.66M) | (447.56M) | (18.80M) | (95.86M) | (91.42M) | 56.28M |
| FCF / Share | 0.08 | 0.02 | 0.20 | 0.02 | -0.13 | -0.26 | -0.30 | -25.82 | -1.09 | -5.55 | -5.16 | 3.20 |
| Operating CF | 32.88M | 44.78M | 62.42M | 7.29M | (31.34M) | (62.93M) | (73.92M) | 97.61M | 86.28M | 75.79M | 78.81M | 72.58M |
| Total Assets | 1.16B | 1.13B | 984.57M | 955.06M | 291.58M | N/A | N/A | 3.27B | 2.96B | 2.68B | 2.61B | 3.07B |
| Total Debt | 430.96M | 378.99M | 426.74M | 418.98M | 419.83M | N/A | N/A | 2.26B | 1.82B | 1.83B | 1.75B | 2.21B |
| Cash & Equiv | 821.15M | 797.80M | 753.22M | 718.93M | 31.20M | N/A | N/A | 47.03M | 38.81M | 47.91M | 53.55M | 42.30M |
| Book Value | 593.49M | 577.31M | 478.36M | 452.90M | (2.60B) | N/A | N/A | 800.72M | 756.26M | 726.21M | 702.24M | 699.03M |
| Return on Equity | -0.00 | 0.14 | 0.05 | -0.16 | N/A | N/A | N/A | 0.06 | 0.05 | 0.05 | 0.02 | 0.02 |
